Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΡΡ ΠΆΠ΅Π»Π΅Π· ΠΈ ΠΈΡ ΠΏΡΠΎΡΠΎΠΊΠΎΠ² Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π³ΠΈΠΏΠ΅ΡΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΠ΅ΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½Π΅Π·Π° ΠΈ Π½ΠΎΡΠΌΠΎΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³Π°Π»Π°ΠΊΡΠΎΡΠ΅Π΅ΠΉ
Π ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π€ΠΠ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ΅ ΠΌΠ΅ΡΡΠΎ Π·Π°Π½ΠΈΠΌΠ°ΡΡ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ — Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠΎΠ·, Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Π»ΡΡΠ΅ΠΈΠ½ΠΎΠ²ΠΎΠΉ ΡΠ°Π·Ρ ΠΌΠ΅Π½ΡΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Π°), Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠΈΡΠΎΠ²ΠΈΠ΄Π½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠ°Ρ Π°ΡΠ½ΡΠΉ Π΄ΠΈΠ°Π±Π΅Ρ, Π³ΠΈΠΏΠ΅ΡΠΊΠΎΡΡΠΈΡΠΈΠ·ΠΌ, Π°ΠΊΡΠΎΠΌΠ΅Π³Π°Π»ΠΈΡ. Π ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π±ΠΎΠ»ΡΡΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΈΠ΄Π°Π΅ΡΡΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΠΌ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌ, Π½ΠΎ ΠΈ Π°ΡΡΠΎΠΊΡΠΈΠ½Π½ΠΎΠΉ ΡΠ΅ΠΊΡΠ΅ΡΠΈΠΈ Π³ΠΎΡΠΌΠΎΠ½ΠΎΠ²… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅
- Π‘ΡΡ
- ΠΠ»Π°Π²Π° 1. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ. Π‘ΡΡ
- 1. 1. Π£ΡΠ°ΡΡΠΈΠ΅ ΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π° Π² ΠΌΠ°ΠΌΠΌΠΎΠ³Π΅Π½Π΅Π·Π΅. Π‘ΡΡ
- 1. 2. Π£ΡΠ°ΡΡΠΈΠ΅ ΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π° Π² ΠΊΠ°Π½ΡΠ΅ΡΠΎΠ³Π΅Π½Π΅Π·Π΅. Π‘ΡΡ
- 1. 3. ΠΡΠΎΠ»Π°ΠΊΡΠΈΠ½ ΠΈ ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΠΊΠΈΡΡΠΎΠ·Π½Π°Ρ ΠΌΠ°ΡΡΠΎΠΏΠ°ΡΠΈΡ Π‘ΡΡ
- 1. 4. ΠΠΎΡΠΌΠΎΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΡΠ΅ΡΠΊΠ°ΡΠ³Π°Π»Π°ΠΊΡΠΎΡΠ΅Ρ. Π‘ΡΡ
- ΠΠ»Π°Π²Π° 2. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ. Π‘ΡΡ
- ΠΠ»Π°Π²Π° 3. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΈΡ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π‘ΡΡ
Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ Π³ΡΡΠΏΠΏ. Π‘ΡΡ. 36. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ Π³ΠΈΠΏΠ΅ΡΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΠ΅ΠΉ. Π‘ΡΡ. 37. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π³ΠΎΠ½ΠΈΡΡΠ°ΠΌΠΈ Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π° Π½Π° ΡΡΡΡΠΊΡΡΡΡ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π‘ΡΡ. 47. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΈΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΈ Π΄ΡΠΊΡΠΎΠ³ΡΠ°ΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π³ΠΈΠΏΠ΅ΡΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³Π°Π»Π°ΠΊΡΠΎΡΠ΅Π΅ΠΉ. Π‘ΡΡ. 52. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ Π½ΠΎΡΠΌΠΎΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³Π°Π»Π°ΠΊΡΠΎΡΠ΅Π΅ΠΉ Π‘ΡΡ. 56. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π³ΡΡΠΏΠΏ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ Π½ΠΎΡΠΌΠΎΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ
ΠΠΈΠΏΠ΅ΡΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³Π°Π»Π°ΠΊΡΠΎΡΠ΅Π΅ΠΉ Π‘ΡΡ. 67.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Π³ΡΡΠΏΠΏΡ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ. Π‘ΡΡ. 70.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ. Π‘ΡΡ. 72. ΠΡΡΠΏΠΏΠ° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ, ΠΊΠΎΡΠΎΡΡΠΌ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Ρ ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅. Π‘ΡΡ. 76.
ΠΡΠ²ΠΎΠ΄Ρ. Π‘ΡΡ. 86.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ°Π»Π°Π±ΠΎΠ»ΠΊΠΈΠ½ Π.Π. «ΠΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΡ», Π. Π£Π½ΠΈΠ²Π΅ΡΡΡΠΌ ΠΏΠ°Π±Π»ΠΈΡΠΈΠ½Π³, 1998 Π³., ΡΡΡ. 134. 2. ΠΡΡΠ΄ΠΈΠ½Π° Π. Π. «ΠΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½Π°Ρ ΡΠ΅Π³ΡΠ»ΡΡΠΈΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΡΡΠ°ΠΏΠΎΠ² ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΌΠΎΠ»ΠΎΡΠ½ΡΡ ΠΆΠ΅Π»Π΅Π·». ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΠ΅ΡΠ²ΠΎΠΉ ΠΡΠ΅ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΠ°ΡΡΠ½ΠΎ
- ΠΠΎΠ½ΠΎΠ½ΠΎΠ²Π° Π.Π€. «Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΡΡ ΠΆΠ΅Π»Π΅Π· Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΡΠ³ΠΈΠΏΠ΅ΡΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠΉ Π°ΠΌΠ΅Π½ΠΎΡΠ΅Π΅ΠΉ ΠΈ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° Π½Π΅Π³ΠΎ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠ°ΡΠ»ΠΎΠ΄Π΅Π»ΠΎΠΌ.»
- Π. ΠΠΊΡΡΠ΅ΡΡΡΠ²ΠΎ ΠΈ Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ, № 5, 1991 Π³ΠΎΠ΄, ΡΡΡ. 47−50.12. Π Π°Π΄Π·ΠΈΠ½ΡΠΊΠΈΠΉ Π. Π., ΠΡΠ΄ΠΈΡΠ½Ρ Π. Π. «ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΠΉ ΠΏΠΎΠ΄Ρ ΠΎΠ΄ ΠΊ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΠΌΠ°ΠΌΠΌΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ».
- Π. ΠΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ, 2003 Π³., № 4, ΡΠΎΠΌ 5, ΡΡΡ. 144−146.13. Π‘ΠΌΠ΅ΡΠ½ΠΈΠΊ Π. Π., Π’ΡΠΌΠΈΠ»ΠΎΠ²ΠΈΡ Π. Π. «ΠΠ΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½Π°Ρ Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ.» Π.
- ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ΅ ΠΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ΅ ΠΠ³Π΅Π½ΡΡΡΠ²ΠΎ, 2000 Π³., ΡΡΡ. 560.14. Π‘ΡΠΎΠ»Π» Π. Π, ΠΏΠΎΠ΄ ΡΠ΅Π΄. «ΠΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΠΈ ΡΠ°ΠΊ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ»,
- Π.ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 1984 Π³. ΡΡΡ 34.15. Π‘ΡΡΡΠΈΠ° Π. Π’. «ΠΡΡΠ΅ΠΊΡ ΠΏΠ°ΡΠ»ΠΎΠ΄Π΅Π»Π° ΠΈ ΡΠΈΡΠΎΠ»ΠΈΠ±Π΅ΡΠΈΠ½Π° Π½Π° ΡΠ΅ΠΊΡΠ΅ΡΠΈΡ ΠΏΡΠΎΠ»Π°ΠΊΡΠΈΠ½Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΏΠ°ΡΠΈΠ΅ΠΉ.» ΠΡΠΎΠ±Π»Π΅ΠΌΡ
- ΠΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΠΈ, 1983 Π³., № 2, 29, ΡΡΡ. 21−24.16. Π§ΠΈΡΡΡΠΊΠΎΠ² Π‘, ΠΡΠ΅Π±Π΅Π½Π½ΠΈΠΊΠΎΠ²Π° Π. Π., Π¨ΠΈΠΊΠΈΠ½Π° Π. Π. «ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ». Π ΠΠ, Π’ΠΎΠΌ 11 № 11, 2003 17. Π¨ΠΈΡ ΠΌΠ°Π½ Π‘Π., Π―ΡΠΎΠ²ΡΠΊΠ°Ρ Π., ΠΠΎΠ½ΠΎΠΏΠΎΠ»ΡΡΠΊΠ°Ρ Π’. Π., Π’ΠΈΡΠΎΠ²Π° Π. Π.,
- Ackrill P, Mansel RE. «Cyclosporin A and multiple fibroadenomas of the breast.»
- Biochem Mol Biol 1990 Dec 20−37(6):977−8142. Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G,
- Minkin S. «The association of breast mitogens with mammographic densities.»
- SK, Dotto GP, Weinberg RA, Jan T. IGF-2 is a mediator of prolactin-inducedmorphogenesis in the breast. Dev Cell 2002 Dec-3(6):877−87 45. Brockman XL, Schroeder MD, Schuler LA.
- ReprodBiol. 1981 Apr-ll (5):341−6.49. Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY. «In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.» Int J
- Oncol 2002 Apr-20(4):813−850. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski
- JE. «Expression of prolactin and prolactin receptor in human breast carcinoma.
- Menopausal Stud. 1994 Sep-Oct-39(5):272−7.62. Francis GL, Hoffman WH, Gala RR, McPherson JC 3rd, Zadinsky J. A „Relationship between neonatal breast size and cord blood testosterone level.“
- Ann Clin Lab Sci. 1990 Jul-Aug-20(4):239−44.63. Gangemi M, Velasco M, Graziottin A, Licori D, Marchesoni D. „Bromoergocriptin therapy in eumenorrhoic patients presenting galactorrhea.“
- Clin Exp Obstet Gynecol. 1981−8(2):79−82.64. Gill S, Peston D, Vonderhaar BK, Shousha S. „Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study.“
- J Clin Pathol 2001 Dec-54(12):956−6065. Ginsburg E, Vonderhaar BK. „Prolactin synthesis and secretion by human breast cancer cells.“ Cancer Res 1995 Jun 15−55(12):2591−5 66. Glasow A, Horn LC, Taymans SE, Stratakis CA, Kelly PA, Kohler U,
- M, Lucas BK, Touraine P, Pezet A, Maaskant R, Pichard C, Helloco C, Baran N,
- Bole-Feysot C, Maaskant RA, Clement-Lacroix P, Edery M, Binart N, Kelly PA."Prolactin: a hormone at the crossroads of neuroimmunoendocrinology.» Ann N
- Gland Biol Neoplasia 1999 Jan- 4(l):79−88.83. Hovey RC, Trott JF, Vonderhaar BK. «Establishing a framework for the functional mammary gland: from endocrinology to morphology.» J Mammary
- Gynakol. 1990−112(17):1091−6.93. Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hayward JL,
- FJ. Benign breast diseases: clinical, radiological and pathological correlation
- Ginecol Obstet ΠΠ΅Ρ . 2002 Dec-70:613−8.113. Murta EF, de Freitas MM, Velludo MA. «Histologic changes in fibrocystic breast disease before and after treatment with bromocriptine.»
- Rev Paul Med. 1992 Nov-Dec-l 10(6):251−6.114. Mussa A, Dogliotti L. «Treatment of benign breast disease with bromocriptine.» J Endocrinol Invest. 1979 Jan-Mar-2(l):87−91. 115. Myhre E. «Is fibrocystic breast disease a pre-malignant state?"Acta Obstet
- Naibunpi Gakkai Zasshi. 1976 Sep 20−52(9):959−71.121. O’Hanlon DM, Kerin MJ, Kent PJ, Skehill R, Maher D, Grimes H, Given
- HF. «A prospective evaluation of CA15−3 in stage I carcinoma of the breast."J
- Am Coll Surg. 1995 Feb-180(2):210−2.122. Ormandy, C.J., A. Camus, J. Barra, D. Damotte, B. Lucas, H. Buteau, M.
- Nicholson RI, Sutherland RL. «Coexpression and cross-regulation of theprolactin receptor and sex steroid hormone receptors in breast cancer.» J Clin
- Endocrinol Metab 1997 Nov-82(l l):3692−9124. Ortega-Gonzalez C, Parra A, Barra R, Aranda C, Ramirez D, Di Castro P,
- Castro I, Zambrana M, Coria I. «Increased hypothalamic dopaminergic tone onlyin early parous women with either malignant or benign breast tumors.» Endocr
- J Endocrinol Invest. 1988 Oct-l l (9):679−83.128. Tamimi RM, Hankinson SE, Colditz GA, Byrne C. «Endogenous Sex 33. Hormone Levels and Mammographic Density among Postmenopausal Women.»
- Minerva Med. 1997 Nov-88(l l):479−87.135. Reynolds Π‘, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. «Expression of prolactin and its receptor in human breast carcinoma.»
- JN. «Mammographic densities and risk of breast cancer.» Cancer. 1991 Junl-67(ll):2833−8. 141. Santoro Π‘, Cappa M, Moretti C, Fabbri A, La Vecchia V, Romano
- Postel-Vinay, Frederique Kuttenn and Paul A. Kelly «Increased Expression of
- Prolactin Receptor Gene Assessed by Quantitative Polymerase Chain Reaction in
- Human Breast Tumors Versus Normal Breast Tissues.» The Journal of Clinical
- Alternative splicing to exon 11 of human prolactin receptor gene results inmultiple isoforms including a secreted prolactin-binding protein.» J Mol
- Endocrinol 2003 Feb-30(l):31−47 157. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE.
- Plasma prolactin concentrations and risk of postmenopausal breast cancer.
- Cancer Res. 2004 Sep 15−64(18):6814−9158. Ueda K, Kato H, Fujino T, Nanjo K, Noguchi H, Numa F, Narimatsu A,
- Nakamura Y, Torigoe T, Ito T, et al. «Use of bromocriptine in the treatment ofnormoprolactinemic infertility."Gynecol Obstet Invest 1987−24(l):62−7 159.Udy, G.B., R.P. Towers, R.G. Snell, R.J. Wilkins, S.-H. Park, P.A. Ram,
- D.J. Waxman, and H.W. Davey. 1997. Requirement of Stat5b for sexualdimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. 1. Sci. 94: 7239−7244 160. Umemura S, Iwasaka T, Kakimoto K, Takahashi A, Koizumi H, Miyakawa
- WD. «Serum oestradiol-17 beta and prolactin concentrations during the lutealphase in women with benign breast disease.» Eur J Cancer Clin Oncol. 1984 1. Nov-20(ll):1345−51. 167. Wang DY, Hampson S, Kwa HG, Moore JW, Bulbrook RD, Fentiman IS,
- Hayward JL, King RJ, Millis RR, Rubens RD, et al. «Serum prolactin levels inwomen with breast cancer and their relationship to survival.» Eur J Cancer Clin
- Oncol. 1986 Apr-22(4):487−92.168. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. «Dopamine antagonists and the development of breast cancer.» Arch Gen
- Matsuda S, Tsushima T, Yamamoto T, Fujita T, Taketani Y, Fukayama M,
- Endocrinol Metab 2003 Feb-88(2):689−96